Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05776225 · ClinicalTrials.gov registry record
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
A clinical trial of Pulmonary Hypertension and Interstitial Lung Disease, sponsored by United Therapeutics.
- Recruiting
- Registry status
- 300
- Enrollment target
- 20
- Study locations
NCT05776225: Recruiting study of Pulmonary Hypertension and Interstitial Lung Disease, sponsored by United Therapeutics.
NCT05776225 is a study of Pulmonary Hypertension and Interstitial Lung Disease that is actively recruiting participants, run by United Therapeutics. The registered enrollment target is 300 participants, below the 609-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05776225, a study of Pulmonary Hypertension and Interstitial Lung Disease, is actively recruiting participants, sponsored by United Therapeutics.
- RECRUITING
- Registry status
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Primary Outcome
Mean pulmonary artery pressure (mPAP) \>20 mmHg with pulmonary artery wedge pressure (PAWP) ≤15 mmHg and pulmonary vascular resistance (PVR) \>2 WU.
Conditions Studied
Interventions
- PROCEDURE Right heart catheterization (RHC)
Study Locations (20)
Florida
- Lakeland Regional Health - Lakeland
- NCH Healthcare System - Naples
- University of South Florida Health - Tampa
- Cleveland Clinic Florida - Weston
Illinois
- Loyola University Chicago - Chicago
- Northwestern University - Chicago
- NorthShore University Health System - Glenview
Georgia
- Emory University Hospital - Atlanta
- Piedmont Healthcare - Austell
Michigan
- University of Michigan Int Med Pulmonary and Critical Care - Ann Arbor
- Mclaren Greater Lansing - Okemos
Arizona
- Pulmonary Associates - Phoenix
Connecticut
- Hartford Hospital - Hartford
Kentucky
- University of Kentucky Medical Center - Lexington
Louisiana
- LSU Health Sciences Center New Orleans - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2023-08-11 |
| Est. Completion | 2026-04 |
What NCT05776225 shows while recruiting
NCT05776225 is an observational study that tracks outcomes without assigning an intervention. The registered 300 participants enrollment target is mid-sized for trials with a published cap, below the 609-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (51% lower).
The record links to 2 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Right heart catheterization (RHC) is the first listed.
NCT05776225 names 20 study sites across 13 states, led by Florida, Illinois, Georgia.
Frequently Asked Questions
What is clinical trial NCT05776225 about?
NCT05776225 is a clinical study titled "Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection". Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
What is the current status of trial NCT05776225?
This trial is currently recruiting. The enrollment target is 300 participants. The study started on 2023-08-11. Estimated completion is 2026-04.
What conditions does trial NCT05776225 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Interstitial Lung Disease.
What interventions are being tested in trial NCT05776225?
The interventions under investigation include: Right heart catheterization (RHC) (PROCEDURE).
Who is sponsoring clinical trial NCT05776225?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05776225 being conducted?
This trial has 20 study locations across Arizona, Connecticut, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05776225's enrollment target sits among peer trials
300 15th of 72 higher than 57 of 72 other Pulmonary Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope
RECRUITING
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
-
Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders
RECRUITING
-
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
RECRUITING · Phase 3
-
Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure
RECRUITING
-
A Trial of Phosphodiesterase-5 Inhibitor in Neonatal Congenital Diaphragmatic Hernia (TOP-CDH)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI